Executive Director and Early Asset Lead
Boehringer Ingelheim Pharma GmbH & Co, Germany
Dr. Sheila Annie Peters serves as an Executive Director at Boehringer-Ingelheim, Germany. She has a PhD in Chemistry from IIT Madras, India. She started her career in Pharma R&D in 1999, working at Cyprotex, UK. Later, she joined AstraZeneca, Mölndal, where she developed and applied a generic whole-body PBPK model to support drug discovery and early development projects across different R&D sites. Here, she won the AstraZeneca Innovative Medicines Science Award for the “Design and Development of LungSim Simulation tool for Inhalation PK Modelling”. Sheila served as Head of Translational Quantitative Pharmacology group at Merck KGaA, Darmstadt for 6 years before taking her current position as Early Asset Lead at Boehringer Ingelheim. Sheila served as the EFPIA Topic leader for the ICH M12 group focused on harmonizing drug-drug interaction (DDI) guidelines. She has published several papers on PK, PBPK, human dose predictions, gut metabolism and DDI in high impact journals and has authored a book on PBPK.
Disclosure information not submitted.
Leveraging Mechanistic Static Models for DDI Waivers and Regulatory Approval
Monday, November 10, 2025
9:00 AM - 9:30 AM CT